Big gain for Deciphera as GIST readout portends face-off with Blueprint

New Phase III data in GIST burnished Deciphera's case for an upcoming regulatory submission, pushing the company's market cap to about $1.4 billion while also taking competitor Blueprint Medicines' shares down a few ticks in Tuesday's trading session.

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) said ripretinib significantly improved progression-free survival (PFS) vs. placebo among fourth-line

Read the full 537 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE